인스타그램·유튜브·틱톡 등 소셜네트워크서비스(SNS) 사용을 스스로 조절하기 어려워 하는 청소년은 시간이 지날수록 주의력결핍과잉행동장애(ADHD) 증상이 더 높아질 가능성이 있다는 연구 결과가 최근 국제학술지 《JAMA ...

A diagnosis can offer parents relief but can also freeze an adult child to being seen as a fixed condition. Letting go of "knowing what's wrong" doesn't mean giving up; it can mean making room for ...

Navigating the challenges of parenting a child with ADHD can be daunting. Tarryn Poulton, a paediatric occupational therapist ...

FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...

Federal authorities convicted a telehealth company founder and clinical president for illegal stimulant prescription ...

Will the new prime minister dare upset the left-wing of his party, which put him in Downing Street, by making benefit payments to young people conditional on them taking part in voluntary work such as ...

Shared genetic architecture may explain the co-occurrence of psychiatric disorders and metabolic abnormalities such as insulin resistance.

HealthDay News — Athletes with attention-deficit/hyperactivity disorder (ADHD) may be more susceptible to sport-related concussion (SRC) and have a longer recovery period, according to a review ...

大塚製薬と米子会社の大塚ファーマシューティカルD＆Cは現地時間の24日、1日1回投与の徐放性製剤「SIMTRIYO（シントリオ）」（海外製品名、一般名＝センタナファジン）について、6歳以上（20kg… ...

Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency. The FDA has ...

A mass shooting at a Seattle festival has left three people dead. And, the U.S. and Iran have been exchanging diplomatic ...

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor ...